Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Cos Eye US' Par Pharma (India)

This article was originally published in PharmAsia News

Executive Summary

Several major Indian pharmaceutical companies are considered possibilities to pursue a takeover of American drug manufacturer Par Pharmaceuticals. Ranbaxy is considered the most-likely choice by market insiders. The company has been looking for promising, U.S. acquisition prospects for some time and Par may represent an opportunity. Wockhardt, Sun Pharma, and Dr. Reddy's are also having their names tossed around. But all of the companies have declined to comment. In fact, Dr. Reddy's denied having any interest in acquiring a U.S.-based company. For its part, Par has several patented drugs in its pipeline; however, most of its interest is in generics. There has been some speculation that the company will sell off its off-patent and patented segments separately, in which case the Indian companies are expected to be interested solely in the generics. Par currently has 100 drugs approved by the U.S. Food and Drug Administration with another 49 applications in the works. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts